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SObjective: Successful pulmonary wedge resection for early-stage non–small cell lung cancer requires a path-
ologically confirmed negative margin. To date, however, no clear evidence is available regarding whether an
optimal margin distance, defined as the distance from the primary tumor to the closest resection margin, exists.
Toward addressing this gap, we investigated the relationship between the margin distance and local recurrence
risk.
Methods:We reviewed all adult patients who had undergone wedge resection for small (2 cm) non–small cell
lung cancer from January 2001 to August 2011, with follow-up through to December 31, 2011. The exclusion
criteria included other active noncutaneous malignancies, bronchoalveolar carcinomas, lymph node or distant
metastases at diagnosis, large cell cancer, adenosquamous cancer, multiple, multifocal, and/or metastatic dis-
ease, and previous chemotherapy or radiotherapy. Using Cox regression analysis, we examined the relationship
between the margin distance and interval to local recurrence, adjusting for chronic obstructive pulmonary dis-
ease, forced expiratory volume in 1 second, smoking, diabetes, tumor size, tumor location, surgeon, open versus
video-assisted thoracoscopic surgery, and whether the lymph nodes were sampled.
Results:Of 557 consecutive adult patients, 479 met our inclusion criteria. The overall, unadjusted 1- and 2-year
local recurrences rate was 5.7% and 11.0%, respectively. From the adjusted analyses, an increased margin dis-
tance was significantly associated with a lower risk of local recurrence (P¼ .033). Patients with a 10-mmmargin
distance had a 45% lower local recurrence risk than those with a 5-mm distance (hazard ratio, 0.55; 95% con-
fidence interval, 0.35-0.86). Beyond 15 mm, no evidence of additional benefit was associated with an increased
margin distance.
Conclusions: In wedge resection for small non–small cell lung cancer, increasing the margin distance15 mm
significantly decreased the local recurrence risk, with no evidence of additional benefit beyond 15mm. (J Thorac
Cardiovasc Surg 2014;147:1169-77)Lung cancer now represents the leading cause of cancer
deaths for men and women.1 Currently, complete surgical
resection is the ideal treatment modality for patients with
early-stage non–small cell lung cancer (NSCLC). Among
the different surgical options, wedge resection has been
the most common limited resection technique used to re-
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The Journal of Thoracic and Cardissection are currently the standard treatment for small
peripheral resectable NSCLC.7 Similarly, many studies on
the changing histopathologic patterns of lung cancer have
been reported. It has been stated that adenocarcinoma has
replaced squamous cell carcinoma as the most frequent his-
tologic subtype for both genders and all races. Recent data
have also suggested that the rate of lung cancer incidence is
greater in women than in men.8 For wedge resection, the
status of the margin and the distance of the tumor from
the resection margin have been major concerns regarding
local recurrence.9-15 In an ongoing phase III randomized
trial of lobectomy versus sublobar resection for small
peripheral NSCLC (Cancer and Leukemia Group B trial
140503), it has been strongly recommended to confirm
the absence of disease in the wedge margin using
histologic or cytologic frozen section analysis. When
performing lung excision for lung cancer, it is mandatory
that malignant cells not be left in the residual pulmonary
parenchyma. However, several other factors during lung
cancer surgery will be important in determining the
survival and recurrence outcomes. These have includeddiovascular Surgery c Volume 147, Number 4 1169
Abbreviations and Acronyms
CI ¼ confidence interval
HR ¼ hazard ratio
NSCLC ¼ non–small cell lung cancer
VATS ¼ video-assisted thoracoscopic surgery
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Sthe degree of histologic differentiation, tumor size, nodal
involvement, and visceral pleural invasion.9,16,17 Within
this framework, however, a paucity of published
information is available on the association between
margin distance and the risk of local recurrence and what
constitutes an optimal margin distance, if such exists, in
pulmonary wedge resection. Specifically, no clear
guidelines are available in the current data regarding the
margin distance from the primary tumor to the closest
margin for wedge resection for small, localized tumors.
The present study, therefore, aimed to characterize the
association between the margin distance in patients who
had undergone wedge resection for small (2 cm)
NSCLC and the local recurrence risk. To address this gap,
we analyzed detailed follow-up data from a cohort of pa-
tients who had undergone successful pulmonary wedge
resection for early-stage NSCLC.METHODS
Study Population
With institutional review board approval, we reviewed the records for all
adult patients who had undergone elective surgical resection for NSCLC
tumors 2 cm at the Brigham and Women’s Hospital (Boston, Mass)
from January 2001 to August 2011. For the present study, we restricted
our attention to pulmonary wedge resections only. All such surgeries
were considered, regardless of whether they had been performed by way
of thoracotomy or video-assisted thoracoscopic surgery (VATS). To focus
our attention on patients with primary NSCLC tumors, we applied the
following exclusion criteria: previous major lung resection, distant previ-
ous thoracic radiotherapy, neoadjuvant therapy before resection, other
active noncutaneous malignancies, pure bronchoalveolar carcinomas,
lymph node or distant metastases at diagnosis, multicentric cancers, large
cell, adenosquamous, and multiple, multifocal, and/or metastatic cancer,
and previous chemotherapy and/or radiotherapy. Figure 1 provides an over-
view of the study population selection and the effect of the various exclu-
sion criteria.
Data Sources
The demographic, clinical, medical and surgical history, and surgical,
pathologic, and intra- and postoperative complication data for all patients
were abstracted from the hospital clinical records. Using the institutional
guidelines, the patients were followed up every 4 months for the first 2
years, every 6 months for years 2 to 5, and annually thereafter. At abstrac-
tion, all variables were comprehensively audited. The original imaging
(chest radiography and computed tomography) studies were reviewed by
a chest radiologist for designation of the location within the hemithorax
and the proximity to any major vessels. Vital status as of December 31,
2011 was determined from the hospital records and through the Social Se-
curity Death Index.1170 The Journal of Thoracic and Cardiovascular SurLocal Recurrence
The primary outcome of interest for the present study was local recur-
rence. In accordance with Martini and Melamed,18 local recurrence was
defined as a tumor of the same histologic type occurring within the same
lobe (or draining hilum and/or mediastinum) or a tumor of the same histo-
logic type in a different lobe or lung with carcinoma in the lymphatics com-
mon to both, and/or extrapulmonary metastases. Disease recurrence was
evaluated by clinical follow-up examination, including chest computed to-
mography, with the date of the first local recurrence documented. Patients
alive on December 31, 2011who had not experienced local recurrencewere
administratively censored.
Margin Distance
The margin distancewas defined as the distance from the primary tumor
to the closest stapled resection margin. The distance was measured by the
pathologist, according to a totally deflated lung, and recorded on the final
pathology report. Because our interest was in the association between the
margin distance and the local recurrence risk, we restricted our analyses
to those patients with a confirmed negative margin. Patients with a positive
malignant margin were excluded from the analyses, just as were patients
with margin distances of<1 mm and those with missing margin data
(Figure 1).
Statistical Analysis
The primary outcome for the present study was the interval to local
recurrence, with the margin distance the primary exposure of interest.
The distributions of the key covariates were calculated and summarized,
stratified by the margin distance (1-5, 6-10, 11-15, and 16-30 mm).
Continuous covariates (eg, margin distance, age, and percentage
of forced expiratory volume in 1 second) were categorized for the
purposes of description but were left in their continuous form for
modeling.
Multivariable Cox regression analysis was used to model the interval to
local recurrence. We adjusted for covariates that were thought, a priori, to
be strong candidates as potential confounders of the association between
the margin distance and the interval to local recurrence. These included
chronic obstructive pulmonary disease, preoperative percentage of forced
expiratory volume in 1 second, smoking status, diabetes, tumor size, tumor
lobe location, location with the hemithorax (inner vs outer half), surgery
type (thoracotomy vs VATS), and whether the lymph nodes had been
sampled. The proximity to a major vessel was not included, because it
correlated highly with the location in the hemithorax. All Cox models
were adjusted for surgeon by stratification of the baseline hazard function.
To ensure a stable estimation of these effects, we restricted attention to op-
erations performed by 8 surgeons who had 10 observations in our data
set; this resulted in the exclusion of 11 surgeries performed by low-
volume surgeons (Figure 1). For our analyses, the follow-up period was
restricted in the analysis to 3 years after surgery owing to the scarceness
of data after that point, possibly invalidating the proportional hazards
assumption of the Cox model. Finally, despite this restriction, a number
of patients died during the follow-up period. To investigate the effect of
death on our results, we repeated all our modeling using a composite
outcome of local recurrence-free survival, in which we considered the in-
terval to the first of death or local recurrence.
In the absence of an a priori hypothesis regarding the form of the margin
distance and interval to local recurrence association, we modeled the asso-
ciation using regression splines to allow for a nonlinear association.19 For
the latter, a single knot was used and set to be the midpoint of the observed
margin distance distribution. To evaluate the statistical significance of the
overall association between the margin distance and local recurrence risk,
we used an omnibus Wald test that jointly evaluated all parameters in the
spline specification. All analyses were performed using R, version 2.15
(R Foundation for Statistical Computing, Vienna, Austria).20 All reported
P values are 2-sided.gery c April 2014
FIGURE 1. Consolidated Standards of Reporting Trials-style diagram illustrating the selection of patients included in the data analysis. NSCLC,
Non–small cell lung cancer.
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SRESULTS
Of 557 consecutive patients, 479 met our primary scien-
tific inclusion and exclusion criteria (Figure 1). The demo-
graphic, clinical, and pathologic information for these
patients are listed in Table 1. Although not included in
Table 1, 41 patients (8.6%) experienced 1 major compli-
cation; only 1 patient (0.2%) died perioperatively.Kaplan-Meier Analyses
Figure 2 shows the Kaplan-Meier plots for local recur-
rence and local recurrence-free survival during the 3 years
of postoperative follow-up, stratified by margin distance.The Journal of Thoracic and CarThe observed overall 1-year local recurrence rate, adjusted
for censoring, was 5.7% (95% confidence interval [CI],
3.1-8.1). The observed overall 2- and 3-year local recur-
rence rate was 11.0% (95% CI, 7.4-14.5) and 16.4%
(95% CI, 11.8-20.9), respectively.Adjusted Models
Of the 479 patients in our sample, 367 had complete data
and were used as the basis for the adjusted analyses. Of the
112 patients not included in the adjusted analyses, 41 had
missing data on the forced expiratory volume in 1 second
(Table 1), 46 had missing chest computed tomographydiovascular Surgery c Volume 147, Number 4 1171
TABLE 1. Demographic, clinical, and surgical characteristics
Characteristic n (%)
Total 479
Gender
Female 307 (64.1)
Male 1172 (35.9)
Age (y)
50 15 (3.1)
51-60 80 (16.7)
61-70 172 (35.9)
71-80 164 (34.2)
>80 48 (10.0)
FEV1%
50 66 (13.8)
51-100 279 (58.2)
>100 93 (19.4)
Missing 41 (8.6)
Tumor location
LLL 56 (11.7)
LUL 141 (29.4)
RLL 86 (18.0)
RML 26 (5.4)
RUL 170 (35.5)
Tumor size (mm)
1-5 14 (2.9)
6-10 104 (21.7)
11-15 226 (47.2)
15-20 135 (28.3)
Margin distance (mm)
1-5 169 (35.3)
6-10 123 (25.7)
11-20 138 (28.8)
>20 49 (10.2)
Histologic type
Adenocarcinoma 367 (76.6)
Squamous cell 91 (19.0)
Other NSCLC* 21 (4.4)
Surgery type
Open 202 (42.4)
VATS 274 (57.6)
Lymph nodes sampled
No 324 (67.6)
Yes 155 (32.4)
FEV1%, Percentage of forced expiratory volume in 1 second; LLL, left lower lobe;
LUL, left upper lobe; RLL, right lower lobe; RML, right mid-lobe; RUL, right upper
lobe; NSCLC, non–small cell lung cancer; VATS, video-assisted thoracic surgery.
*Cases in which the pathologist was sure the tumor was not small cell but could
not differentiate between adenocarcinoma and squamous cell cancer.
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volume surgeons, and 14 had a margin distance>30 mm
(Figure 1; see also, the ‘‘Statistical Analysis’’ section). A
detailed graphic representation of the spline-based
nonlinear trend in the smooth hazard ratio (HR) association
between the margin distance and the local recurrence risk,
along with the pointwise 95% CIs, is presented in
Figure 3. Overall, an increased margin distance was signif-
icantly associated with a lower risk of local recurrence1172 The Journal of Thoracic and Cardiovascular Sur(P¼ .033; Figure 3, top), with evidence of diminished addi-
tional benefit beyond a margin distance of approximately 15
mm. Specifically, beyond 15 mm, the downward trend flat-
tened out, indicating diminished benefits of increasing the
margin distance. In contrast, beyond a margin distance of
20 mm, the trend appeared to increase, although, because
the pointwise 95%CI was sowide (owing to the small num-
ber of observed events among the patients with largemargin
distances), this should be interpreted with caution.
Numeric estimates of the HRs, taken from Figure 3,
comparing the risk of local recurrence among patients
with a 5-mm margin distance and patients with varying
margin distances are listed in Table 2. After adjustment
for potential confounding (Table 2, left), the patients with
a margin distance of 2 mm were estimated to have a 54%
greater risk (HR, 1.54; 95% CI, 1.11-2.14) of local recur-
rence than patients with a margin distance of 5 mm. Among
patients with a 10-mmmargin distance, the local recurrence
risk was estimated to be 45% lower than that in patients
with a 5-mm margin distance (HR, 0.55; 95% CI, 0.35-
0.86). As the margin distance increased by another 5 mm,
additional benefits were found, although they were dimin-
ished. The estimated risk of recurrence among patients
with a 15-mm margin distance was 59% lower than the
risk among patients with a 5-mm margin distance (HR,
0.41; 95% CI, 0.21-0.81).
Finally, Table 2, right, and Figure 3, bottom, provide re-
sults from the adjusted models of the association between
the margin distance and local recurrence-free survival.
The results were consistent with those for local recurrence,
in that an increasing margin distance conferred a lower risk
of local recurrence, with no evidence of additional benefit
beyond 15 mm.
DISCUSSION
In the present study, we found that in wedge resection for
small (2 cm) NSCLC, increasing the resection margin dis-
tance significantly decreased the risk of local recurrence.
The patients who underwent pulmonary wedge excision
for small tumors (2 cm) with a 15-mm distance had a
113% lower risk of local recurrence than patients with a
margin distance of 2 mm. Our findings were consistent
with our hypothesis. These results indicate that such a
finding is a significant prognostic factor in wedge resection,
a surgical option for small NSCLC.15,21 The accurate
diagnosis of the wedge resection margins status, the
margin distance, and efficacy to prevent local recurrence
are matters of great concern. It has generally been
accepted that limited lung resection is safe and effective
in a selected group of patients. However, great concern
exists regarding local recurrences. In the published data,
the local recurrence rate for wedge resection has varied
from 2.7% to 30.0% for NSCLC stage I.2-7 What is
unknown is the safe limit of a wedge resection margingery c April 2014
FIGURE 2. Kaplan-Meier plots for local recurrence and local recurrence-free survival during 3 years of postoperative follow-up, stratified by margin
length.
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Sdistance for a small size lung cancer and how the technique
of wedge resection affects the extent of this margin and the
ability to perform facile, prompt, and accurate pathologic
assessments. Furthermore, in the published data, no clear
guidelines are available regarding the margin distance for
small tumors.
The treatment of choice for early-stage, node-negative
NSCLC has been surgical resection, preferably with an
anatomic lobar procedure. In cases in which lobar resection
is not possible because of poor lung function or other major
comorbidity, a segmentectomy or wedge resection can be
accomplished.22 With a limited resection for NSCLC, the
risk of margin relapse can be high. Complete surgical resec-
tion with a negative margin provides the best chance of
cure. A more recent, albeit, single-institution, retrospective
review, found no difference in locoregional recurrence or
disease-free survival between the 2 resection strategies
when the tumor was<2 cm.23 Postoperative radiotherapy
is indicated in the setting of a close or positive margin; how-
ever, in the absence of these criteria, the postoperative
radiotherapy meta-analysis indicated a fairly clear potential
for harm in patients with early-stage NSCLC.24 The risk of
local recurrence after segmentectomy is lower than that af-
ter wedge resection, because with the former, a greaterThe Journal of Thoracic and Carvolume of tissue is removed and has a lower potential of
leaving residual tumor cells at the surgical margin, which
could lead to a lower risk of local recurrence. In general,
the larger the margin, the better. El-Sherif and colleagues25
postulated that a large proportion of local recurrence will be
related to an inadequate resection margin and reported that
the margin is an important consideration in surgical resec-
tion for NSCLC.Wedge resection has frequently been asso-
ciated with a margin <1 cm and a high risk of local
recurrence. Sawabata and colleagues,26 in a multicenter
prospective study, suggested that when the margin distance
was greater than the maximum tumor diameter, the chances
for margin relapse were low. Sawabata and colleagues,27 in
another study, suggested that pulmonary wedge resection
for peripheral tumors should result in negative malignant
margins, which could be obtained from a sufficient tumor
margin ratio of 1. Our results correlate with those from
El-Sherif and colleagues25 that a margin distance of>1
cm is associated with a lower risk of local recurrence. Addi-
tionally, we found that as the margin distance increased, the
risk of local recurrence decreased, which correlated with
the findings from Sawabata and colleagues.26,27
Our study had a number of important strengths arising
from the rigorous and detailed data collection of a broaddiovascular Surgery c Volume 147, Number 4 1173
FIGURE 3. Adjusted hazard ratios from Cox regression model for the association between margin length and risk of (A) local recurrence and (B) local
recurrence or death. The solid line represents the ratio of the hazard for the given outcome for the corresponding margin distance to the hazard for the
outcome for a referent margin distance of 5 mm, holding adjustment covariates constant. Dashed lines represent pointwise 95% confidence intervals.
TABLE 2. Adjusted hazard ratios from Cox models of association
between margin distance and local recurrence risk and risk of local
recurrence or death
Margin distance (mm)
HR* (95% CI)
Local recurrencey
Local recurrence
or deathz
2 1.54 (1.11-2.14) 1.29 (1.02-1.64)
5 Referent Referent
10 0.55 (0.35-0.86) 0.70 (0.51-0.95)
15 0.41 (0.21-0.81) 0.56 (0.34-0.90)
20 0.46 (0.20-1.04) 0.54 (0.29-1.02)
HR, Hazard ratio; CI, confidence interval. *Adjusted for chronic obstructive pulmo-
nary disease, forced expiratory volume in 1 second, smoking, diabetes, tumor size,
tumor lobe location, location within the hemithorax, surgeon, open versus video-
assisted thoracic surgery, and whether lymph nodes were sampled. yP ¼ .033,
omnibus Wald-based P value for overall association. zP ¼ .058, omnibus
Wald-based P value for overall association.
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Srange of factors, including comprehensive long-term
follow-up, for a large cohort of patients with early-stage
NSCLC. Methodologically, the control for a broad range
of potential confounders and the adjustment for missing
data, using multiple imputations, mitigated bias and, we
believe, strengthened our results and conclusions. Several
limitations of our study also merit discussion. First, this
was a retrospective analysis of the results for surgery per-
formed by a variety of surgeons with variable technique
used, including a mixture of VATS and open surgery and
variable pathologic nodal staging in the form of preopera-
tive mediastinoscopy or intraoperative lymph node sam-
pling. In many cases, the resection was performed for
both diagnostic and therapeutic intervention. Second, just
as with all observational studies, our results could have suf-
fered from unobserved residual confounding. Nevertheless,
our analyses were comprehensive in that we used our exten-
sive administrative databases to perform a rich adjustment
for confounding, including the adjustment for patient- and
surgeon-specific effects. Given the strength of the observed
association between the margin distance and the risk of
local recurrence, we do not believe that sufficient residual
confounding were present to reverse our conclusions. Third,1174 The Journal of Thoracic and Cardiovascular Surwe did not investigate the difference between the VATS and
open approaches in regard to the margin distance and/or
local recurrence. The final limitation was the potential for
selection bias that results from analyzing the data collected
after a rigorous pathologic review with the study inclusion
criteria in which patients with positive margins, repeatgery c April 2014
Mohiuddin et al General Thoracic Surgeryresection, multifocal disease, induction therapy, distant me-
tastases, large cell cancer, and adenosquamous cancer were
all excluded. Although this limited the generalizability of
these results, it has enhanced the validity by reducing the
heterogeneity in the study population.G
T
SCONCLUSIONS
The focus of the present study was on the distance from
the primary tumor to the closest margin in wedge resection.
Crucially, we could not report on the differential effect that
the margin distance might have for tumors of different sizes
because we did not have enough power to detect the effect.
However, we did not restrict the results to a specific postu-
lated margin-to-tumor size ratio but, rather, quantified the
effect of the margin distance, in general, on the risk of recur-
rence. We found that an increasing margin distance yielded
decreased local recurrence rates for a margin distance of
15 mm, regardless of the tumor size when the tumors
were 2 cm. Thus, we can decrease the risk of local recur-
rence during wedge resection of small NSCLC if we can
achieve an adequate (15 mm) margin distance. Although
we believe our results speak to the potential benefits associ-
ated with a resection margin of 15 mm, they cannot
specify the ideal margin distance for small tumor size. Our
results suggest that an important avenue for future work
will be to gather more data from patients from other insti-
tutes and to further determine the optimal margin distance
for small tumors. This association should be investigated
in future studies that explicitly consider the relationship be-
tween the margin distance and local recurrence.References
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Dr Joshua R. Sonett (New York, NY). Thank you for your
excellent presentation and for the rather significant effort and en-
ergy to collect, analyze, and study this large cohort of patients.
Having pathologic data with long-term follow-up of patients
who underwent wedge resection for this is important, because
our treatment options for early-stage lung cancer are continually
debated, not only by surgeons. As our less invasive options for
treating lung cancer are introduced, we need to ensure we do not
diminish our cure rates at the heels of ease, expediency, and
minimalism.
Your results build on the results from El-Sherif in that 1-cm
margins are important, and you conclude that>1.5 cm might be
the point of diminishing return. I, similar to probably half this audi-
ence, do not understand spline statistics, but I had a very competent
statistician look at it for me. They thought your data were donediovascular Surgery c Volume 147, Number 4 1175
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Svery well in terms of the statistics, although the>1.5-cm popula-
tion was a little bit low in the number of patients you had, those
with margins>1.5 cm.
I have several questions, more about the philosophy for wedge
resection and how you responded to the results. By the age of your
patients when I read your report, the pulmonary function, which
was pretty reasonable in a large population, and the tumor location,
which was predominantly right upper lobe, left upper lobe, and
middle lobe, it appears to me that these patients would have easily
tolerated much larger resections. So, how do you presently decide,
short of the currently randomized Cancer and Leukemia Group B
(CALGB) trial, in which patients with<2-cm tumors receive a
wedge resection?
Dr Mohiuddin. Thank you very much.
We presently decide according to patient age, tumor size, tumor
location, percentage of forced expiratory volume in 1 second
(FEV1), distant metastasis, and patient comorbidities. Those are
our criteria.
Dr Sonett. In your data, 60% of your patients had<1-cm mar-
gins and 67% had no lymph nodes sampled. Again, this was by
very competent thoracic surgeons. So, what is your current prac-
tice for lymph node sampling in these patients? Do you think it
is relevant in this cohort to sample the lymph nodes, and how
can you advocate for surgical resection instead of, say, stereotactic
body radiotherapy (SBRT) if we are not going to sample the nodes
and achieve>1-cm margins?
Dr Mohiuddin. Our current practice is to take the lymph nodes,
and we strongly think it is relevant to sample the lymph nodes. How
weadvocate surgical resection overSBRT,webelieve surgical resec-
tion has more advantages and benefits, such as sampling the lymph
nodes. With SBRT, we cannot sample the lymph nodes. No long-
term data are yet available on the effect of radiation on the lungs.
Dr Sonett. Much of the published data, and I would say
including the last report and Dr Faber’s discussion, have shown
improved results with segmental resection. Now, it is not clear
whether the benefit of segmental resection results from actually
removing the anatomic segment and lymphatics versus just attain-
ing a good, safe margin. Given your data presented, do you mea-
sure the distance of your margin in the operating room and
consider performing either a larger resection or segmentectomy
if the margin is not adequate as you had defined?
Dr Mohiuddin. We ensure that the surgical resection margin is
negative in the operating room, and we do measure the distance,
and we do consider performing a larger resection or a segmentec-
tomyor lobectomy if the patient has an adequate percentage of FEV1.
DrSonett.So, as opposed to the historical data, now that youhave
shown these data, if youwere to performawedge resection right now
with a<1-cm margin, what would be your course of events?
Dr Mohiuddin. Sorry, can you repeat the question?
Dr Sonett. If you were to perform a wedge tomorrow for a
lesion and, pathologically, on frozen section analysis, the margin
was<1 cm, what would be your answer in the operating room?
Dr Mohiuddin.We have 2 options. It all depends on the FEV1
for determining whether we can go back and resect at the same
time.
Dr Scott J. Swanson (Boston, Mass). I can maybe answer that.
Kamran is a fellow, and I think he is not going to really make that
decision. I think our philosophy based on the learning from this1176 The Journal of Thoracic and Cardiovascular Surdatabasewould be to perform amore aggressive resection, whether
segmentectomy or lobectomy, with nodal dissection, and I think
this has been pretty informative for us. The points you brought
up are pretty revealing. So, we are taking this forward to do a
more aggressive resection. But, is 15 mm the right number? I do
not think we know that. However, if we believe that we are not
at least over the tumor diameter ratio, I think most of us would
do a larger resection.
Dr Sonett. Well, if you consider Dr Altorki’s results, you
consider your results, and you consider the prospective trial on ra-
diation seeds that was presented at the Southern, those 3 trials, all
by really good, dedicated thoracic surgeons, all hadmiserable mar-
gins. So it would be hard for us to advocate for surgery when we
are achieving crappy margins against SBRT. I think we as a group
have to either do better segmental resections or perform lobec-
tomies, but we cannot perform a crappy wedge resection with
small margins just to try to keep pace with SBRT, because we
will not be doing anybody a favor, including ourselves and our
patients.
Dr Harvey Pass (New York, NY). I would like to follow-up on
what Josh said and also to ask the Brigham group. The Brigham
group is known, not only for terrific thoracic surgery, but also for
terrific radiology imaging. My problem as an old surgeon is where
is the lesion? There are easy wedges, and there are deep wedges
that are not very easy. You have a study that considered themargins
and you also have imaging studies for all these patients. Is not this
the perfect study to also correlate the image findings preoperatively
of where the lesion is andwhether you could actually document be-
forehand whether you could perform an adequate resection? The
deeper lesions will be the ones that, yes, you find you cannot resect
and achieve a 1-cm margin, but you cannot do another resection;
you must use segmentectomy. As I get older, I like to plan and
know what I will have to do beforehand. I think that your imaging
data at the cross-sectional diameter, where this is, and the distance
from the hilum as a uniform point, or from the visceral pleura,
could be very enlightening regarding whether you approach a
case as a wedge or segmentectomy.
Dr Mohiuddin. I agree with you. Thanks.
Dr Daniel L. Miller (Atlanta, Ga). We are killing ourselves
here. I mean from the point of view of lymph node evaluation,
we suck: 67%, nothing in this. The previous study, 44%. We are
giving these cases away. That is not acceptable. I am sorry; it is
not. Wemust do a better job at that or we are going to lose this busi-
ness. SBRT results in a 5-mmmargin.We are coming down to their
level. We must do better than that. Now, I think it is embarrassing
that we have these studies that show that. If the values are not there,
we take that out of our analysis. But we must do a better job or we
are going to lose this.
My 1 question I have is, did you consider the biohistologic fea-
tures of the tumor? Was there a difference in the lymphatic inva-
sion, neuroinvasion, and vascular invasion and was there a
difference in visceral pleural invasion? I think that considers recur-
rence and so forth, but we must do better.
DrMohiuddin. I agree with you. We did include lymphovascu-
lar invasion and pleural invasion, and we adjusted for that in our
analysis.
DrMiller. But, did you have to resect a larger volume for those
patients?gery c April 2014
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we cannot comment on that.
Dr Michael I. Ebright (Boston, Mass). I am going to follow-up
on Dr Pass’s point. Previous studies have suggested that tumors
within the central one third of the lung, the central tumors, will
have up to a 50% rate of lymph node metastases. As one’s tumors
become more central, it becomes more technically difficult or
perhaps not even feasible to perform a sublobar resection with a
wedge, and we might need to default to segmentectomy, even if
that would not be our initial preferred approach. I would assume
that most of the tumors in your studies were peripheral, but I am
wondering whether you have any data to suggest whether you are
treating the peripheral tumors differently than the central tumors.
Dr Mohiuddin. I agree. In our data we have had more periph-
eral tumors. That was determined by the radiologic evaluation.
The radiologist evaluated within the hemithorax the location,
and from our data, you are right.
Dr David C. Rice (Houston, Tex). How did you measure your
margin? The Sawabata report measured it from the cut edge of
the staple line and did smears on that; thus, that little 5-mm bit
was included in their margin.
I also want to make a comment. We are shooting ourselves in the
foot if we continue to call this local recurrence, because the radiationThe Journal of Thoracic and Caroncologists, like it or not, are not going to playbyour rules.Theyhave
termed recurrence at the tumor site ‘‘local recurrence.’’ This is really
locoregional recurrence if you are including the lymph nodes. I
would beg you to include that in your report, at least make it clear,
so that an internist will at least be able to compare appleswith apples.
Dr Mohiuddin. The resection margin was evaluated by the
pathologist, and it was the distance from the tumor to the resection
margin, not including the staple line.
I am sorry, can you repeat the second question?
Dr Rice. That is okay. It was just a comment.
Dr Gunda Leschber (Berlin, Germany). I would like to come
back to this margin and the measurement of the margin. You said
the pathologist measured it, but was it with an inflated lung or was
it in a formalin-fixed lung? When was it measured? We know that
the margin will shrink if we put it in formalin.
Dr Mohiuddin. It was in an inflated lung.
Dr Thomas Rice (Cleveland, Ohio). I am curious about your
need to create a new term. ‘‘Margin length.’’ I expected you to
measure the length of the margin. Why did you not call it what
we all call it—the distance from the primary tumor to the closest
margin. Be precise. Be accurate. You are a surgeon. I would
change your term ‘‘margin length.’’
Dr Mohiuddin. Thank you.diovascular Surgery c Volume 147, Number 4 1177
